Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
888
datasets available to search
ShareScore release 0.9.0
Dataset results
888 results for “insulin resistance”
Data from: mPRIME Study - Interaction of Insulin Resistance with Cognition, Lifestyle, and Mental Health
<p>The presented datasets were collected within the <em>m</em>PRIME study, a prospective, observational study of the H2020 project Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME) (grant No. 847879). The study investigates the interaction of insulin resistance with cognition, lifestyle, and mental health by combining traditional methods with ambulatory assessment and sensor-based data collection. Recruitment took place between March 2021 and March 2023 at the University Hospital Frankfurt, Germany.</p> <p>The eligibility criteria for the study were as follows: Age above 18 years, no intake of antidiabetic medication, insulin or glucocorticoids, no existing type 1 diabetes mellitus or gestational diabetes, no diagnoses of bipolar I disorder, schizophrenia, organically caused mental disorders and substance dependence, no severe neurological disorders, no current pregnancy or breastfeeding, no non-correctable visual impairments, no participation in medication-related studies within the last 6 months, no use of weight-reducing medications or a diet within the last 3 months, sufficient proficiency in German to complete questionnaires and neuropsychological tests.</p> <p>All participants in the <em>m</em>PRIME study provided written informed consent. The study protocol and procedures were approved by the local ethics committee.</p> <p><strong>Study Design</strong></p> <p>Individuals completed a baseline assessment and a one-week ambulatory assessment. The baseline assessment included: socio-demographic information, blood samples, anthropometric measures, neuropsychological tests, and several questionnaires. In addition, individuals were introduced to smartphone-based ecological momentary assessment (EMA), food protocols, and the use of sensors (continuous glucose monitor, accelerometer). Food protocols and EMA were conducted on three consecutive days, including two weekdays and one weekend day (Thursday to Saturday or Sunday to Tuesday). Several times a day, individuals were prompted via their smartphone to complete a working memory task and answer questions about stress, affect, and food intake. The continuous glucose monitor and accelerometer were worn continuously for 1 week.</p> <p> </p>
Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure. Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.
<p>Figure S1. Mediation analysis on the effect of insulin resistance on intraocular pressure.</p> <p>Figure S2. Forest plot showing the OR (95% CI) for EIOP of ALD versus NAFLD and the OR (95% CI) for EIOP of drinkers versus non-drinkers. Abbreviations: OR, odds ratio; CI, confidence interval; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease.</p>
Metallomics in childhood obesity, insulin resistance, and related susceptibility factors
<p>Metallomics data from plasma and red blood cell (RBC) samples collected from a population-based cohort of children with obesity and healthy controls</p>
Metabolomics in childhood obesity, insulin resistance, and related susceptibility factors
<p>Metabolomics data from plasma and red blood cell (RBC) samples collected from a population-based cohort of children with obesity and healthy controls</p>
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER St
ClinicalTrials.gov study NCT04216589. IPD Sharing: YES. Countries: 2. Publications: 2.
Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver
The classical drug development pipeline necessitates studies using animal models of human disease to gauge future efficacy in humans, however there is a low conversion rate from success in animals to humans. Non-alcoholic fatty liver disease (NAFLD) is a complex chronic disease without any established therapies and a major field of animal research. We performed a meta-analysis with meta-regression of 603 interventional rodent studies (10,364 animals) in NAFLD to assess which variables influenced treatment response. Weight loss and alleviation of insulin resistance were consistently associated with improvement in NAFLD. Multiple drug classes that do not affect weight in humans caused weight loss in animals. Other study design variables, such as age of animals and dietary composition, influenced the magnitude of treatment effect. Publication bias may have increased effect estimates by 37-79%. These findings help to explain the challenge of reproducibility and translation within the field of metabolism.
Reduced gray matter volume in the default-mode network associated with insulin resistance
<p>Insulin resistance may lead to structural and functional abnormalities of the human brain. However, the mechanism by which insulin resistance impairs the brain remains elusive. In this study, we used two large neuroimaging databases to investigate the brain regions where insulin resistance was associated with the gray matter volume and to examine the resting-state functional connectivity between these brain regions and each hypothalamic nucleus. Insulin resistance was associated with reduced gray matter volume in the regions of the default-mode and limbic networks in the cerebral cortex in older adults. Resting-state functional connectivity was prominent between these networks and the paraventricular nucleus of the hypothalamus, a hypothalamic interface connecting functionally with the cerebral cortex. Furthermore, we found a significant correlation in these networks between insulin resistance-related gray matter volume reduction and network paraventricular nucleus of the hypothalamus resting-state functional connectivity. These results suggest that insulin resistance-related gray matter volume reduction in the default-mode and limbic networks emerged through metabolic homeostasis mechanisms in the hypothalamus.</p>
Yogurt supplementation attenuates insulin resistance in obese mice by reducing metabolic endotoxemia and inflammation
<p><strong>Background</strong></p> <p>Inflammation is an underlying mechanism for development of obesity-related health complications. Yogurt consumption inhibits obesity-associated inflammation, but the tissue-specific mechanisms have not been adequately described.</p> <p><strong>Objectives</strong></p> <p>We aimed to determine the tissue-specific responses by which yogurt supplementation inhibits inflammation.</p> <p><strong>Methods</strong></p> <p>C57BL/6 male mice (5 weeks old) were fed a Teklad Global 14% Protein Rodent Maintenance diet as a control or a high-fat diet (60% calories from fat) to induce obesity for 11 weeks, followed by feeding a Western diet (WD; 43% carbohydrate & 42% fat) or WD supplemented with 5.6 % lyophilized yogurt powder for 3 weeks to test for the impact of yogurt supplementation. Markers of metabolic endotoxemia and inflammation were assessed in plasma and tissues. Cecal and fecal microbiota were profiled by 16S rRNA sequencing.</p> <p><strong>Results</strong></p> <p>In obese mice, relative to the WD control group, yogurt supplementation attenuated HOMA-IR by 57%) (p=0.020), plasma TNF-a by 31% (p<0.05) and colonic IFN-g by 46% (p=0.0034), which were accompanied by a 40% reduction in plasma LBP (p=0.0019) and 45% less colonic <em>Lbp</em> expression (p=0.037), as well as alteration in the beta diversity of cecal microbiota (p=0.0090) and relative abundance of certain cecal microbes (e.g., <em>Lachnospiraceae Dorea longicatena</em> with p=0.049). There were no differences in the LBP, <em>Lbp</em>, and <em>Cd14</em> levels in the liver and small intestine between obese mice with and without yogurt supplementation (p>0.05).</p> <p><strong>Conclusions</strong></p> <p>Yogurt consumption inhibited obesity-induced inflammation in mice by modulating colonic endotoxin detoxification, changing the gut microbiota, and improving glucose metabolism. This work helps to establish the underlying mechanisms by which yogurt consumption affects markers of metabolic and immune health.</p>
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov study NCT02426541. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
ClinicalTrials.gov study NCT00665353. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Inflammation and Insulin Resistance in Rheumatoid Arthritis
ClinicalTrials.gov study NCT00763139. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
ClinicalTrials.gov study NCT02437084. IPD Sharing: NO. Countries: 1. Publications: 20.
Insulin Resistance in Non-alcoholic Fatty Liver Disease
ClinicalTrials.gov study NCT00252499. IPD Sharing: Not stated. Countries: 1. Publications: 2.
EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance
ClinicalTrials.gov study NCT00618072. IPD Sharing: Not stated. Countries: 1. Publications: 6.
A Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes
ClinicalTrials.gov study NCT04118374. IPD Sharing: YES. Countries: 1. Publications: 1.
Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance
ClinicalTrials.gov study NCT00954109. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
ClinicalTrials.gov study NCT03011775. IPD Sharing: NO. Countries: 1. Publications: 1.
Effects of Fish Oils on Inflammation and Insulin Resistance
ClinicalTrials.gov study NCT00579436. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
ClinicalTrials.gov study NCT00130286. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
ClinicalTrials.gov study NCT00339833. IPD Sharing: Not stated. Countries: 1. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.